CLASS II Drug recall · Reported 8 May 2019 · FDA Enforcement Report
Bevacizumab 1.25 mg/ MJ syringe Intravitreal Injection recalled
Pacifico National is recalling Bevacizumab 1.25 mg/ MJ syringe Intravitreal Injection, distributed nationwide in the US. The recall was initiated on 19 Apr 2019 and the FDA has classified it as Class II.
Check your package
Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.
Recall details
- Recall number
- D-1271-2019
- FDA event ID
- 82676
- Recalling firm
- Pacifico National, Melbourne, FL
- Classification
- Class II
- Status
- Terminated
- Recall initiated
- 19 Apr 2019
- FDA classified
- 7 May 2019
- Reported
- 8 May 2019
- Type
- Voluntary: Firm initiated
- Customers notified by
- Telephone
- Reason category
- Packaging Defects
- Drug class
- Injectable & IV Drugs
Timeline
| 19 Apr 2019 | Recall initiated by company | |
| 7 May 2019 | Classified by FDA | +18 days |
| 8 May 2019 | Published in enforcement report | +1 day |
Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.
Reason for recall
Defective Delivery System: difficult to express
Packaging recalls include wrong labels, wrong products in the wrong bottle, missing leaflets, short-filled or empty capsules and seals that fail.
Product as listed by the FDA
BEVACIZUMAB 1.25 mg/0.05 mL 31G MJ syringe Intravitreal Injection. This biologic product was repackaged by AmEx Pharmacy 1515 Elizabeth St. Suite J Melbourne, FL 32901 Lot:190212AB BUD:5/13/2019, Repackaged on 2/12/2019
Where it was distributed
Nationwide in the US
Questions about this recall
Why was it recalled?
Defective Delivery System: difficult to express
Which lots are affected?
Lot: 190212AB BUD: 5/13/2019
Where was it sold?
Nationwide in the US
What should I do if I have it?
Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.
What does Class II mean?
Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.
Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.
More recalls from Pacifico National
All 5| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| Drug | CLASS II | Bevacizumab, 1.25 mg/ MJ Syringe Intravitreal Injection recalled | Pacifico National | Sterility | PR |
| Drug | CLASS II | Bevacizumab, 2.5 mg/, Norm-Ject Syringe Intravitreal recalled | Pacifico National | Sterility | PR |
| Drug | CLASS I | Avastin (Bevacizumab) 1.25 mg/ syringe recalled by Pacifico National | Pacifico National | Sterility | Nationwide |
| Drug | CLASS I | Avastin (Bevacizumab) 2 mg/ syringe recalled by Pacifico National | Pacifico National | Sterility | Nationwide |
Other Bevacizumab recalls
All 16| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| Drug | CLASS II | Bevacizumab 1.75 mg/ - syringe, Intravitreal Total Volume recalled | RC Outsourcing | Sterility | Nationwide |
| Drug | CLASS II | Bevacizumab 1.25 MG/ Solution for Injection syringes recalled | Pine Pharmaceuticals | Sterility | Nationwide |
| Drug | CLASS III | Bevacizumab 2.5 mg/, Solution for Injection recalled | Pine Pharmaceuticals | Packaging Defects | Nationwide |
| Drug | CLASS II | Bevacizumab, 1.25 mg/ MJ Syringe Intravitreal Injection recalled | Pacifico National | Sterility | PR |
| Drug | CLASS II | Bevacizumab, 2.5 mg/, Norm-Ject Syringe Intravitreal recalled | Pacifico National | Sterility | PR |